Improved Efficacy of a Pegylated Interferon-α-2a Stepwise Optimization Treatment Strategy in the Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Patients. Issue 17 (May 2015)

• Record Type: Journal Article
• Authors: Zhou, Pu; Yang, Feifei; Wang, Jinyu; Mao, Richeng; Qi, Xun; Huang, Yuxian; Zhang, Jiming; Huo., Jinhai
• Is Part Of: Medicine. Volume 94:Issue 17(2015)
• Publication Date: 2015-05
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000000730
• Languages: English
• ISSNs: 0025-7974

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Abstract</title> <p>Current pegylated interferon-α (PEG-IFN) treatment for chronic hepatitis B (CHB) e-antigen (HBeAg)-positive patients are suboptimal, and effective ways of improving PEG-IFN treatment efficacy are needed.</p> <p>This retrospective cohort study compared the efficacy of a PEG-IFN stepwise optimization treatment (PEG-IFN SOT) strategy with that of a 48-week PEG-IFN standard therapy (PEG-IFN ST) in HBeAg-positive CHB patients.</p> <p>A total of 110 patients were included in our study. Of these, 70 received the PEG-IFN SOT and 40 received the PEG-IFN ST (control group). We based the decision whether to add adefovir and/or extend the PEG-IFN–based treatment to 96 weeks on the patients' 12-week or 24-week early virological response (12W EVR, at least a 2 log<sub>10</sub> reduction in HBV DNA copies/mL at week 12; 24W EVR, at least 1 log<sub>10</sub> reduction in HBsAg IU/mL or HBsAg <1500 IU/mL at week 24) and their 48-week partial response (48W PR, 1.0 ⩽HBeAg ⩽10.0 S/CO or HBeAg >10.0 S/CO but HBsAg <1000 IU/mL).</p> <p>The HBeAg seroconversion rate 24 weeks post-PEG-IFN treatment was significantly higher in the PEG-IFN SOT than the PEG-IFN ST group (50% vs 22.5%, <italic>P</italic> <italic>=</italic> 0.005). The HBsAg clearance rates in the PEG-IFN SOT and ST groups were 10% and 0% (<italic>P</italic> = 0.04), respectively. Receiving PEG-IFN SOT (OR = 0.26, <italic>P</italic> <italic>=</italic> 0.01), ALT × ULN at baseline (OR = 0.74, <italic>P</italic> <italic>=</italic> 0.003), and achieving 12 and 24W EVR (OR = 0.29, <italic>P</italic> <italic>=</italic> 0.03) were independent factors associated with HBeAg seroconversion.</p> <p>PEG-IFN SOT is a promising strategy for achieving high rates of serological response in HBeAg-positive CHB patients.</p> </sec> </abstract>